EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer's Disease

Read also

Takeda

Takeda walks away from cell therapy in priority U-turn

Taysha Says

Taysha Says FDA Grants Breakthrough Therapy Designation To In Rett Syndrome

Intravitreal Injection of Retinal Progenitor

Intravitreal Injection of Retinal Progenitor Cells Shows Promise in Preclinical Study for Diabetic Retinopathy

Mercury Bio

Mercury Bio Reports Positive Results from Preclinical Study Evaluating Novel Drug Delivery Technology Transporting Protein